Venglustat malate is a Small Molecule owned by Sanofi, and is involved in 6 clinical trials, of which 1 was completed, and 5 are ongoing.

Venglustat malate (GZ-402671) is a glucosylceramide synthase (GCS) inhibitor. Alterations in the level of glucosylceramide are noted in cells and tissues in response to multiple conditions. Up-regulation of glucosylceramide offers cellular protection, cell proliferation. GZ-402671 inhibits the formation of ceramide at the membranes of the endoplasmic reticulum leads to block the biosynthesis of glycosphingolipids from ceramide and decrease the insufficient breaking lipids levels in the body.

The revenue for Venglustat malate is expected to reach a total of $1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Venglustat malate NPV Report.

Venglustat malate was originated by Genzyme and is currently owned by Sanofi.

Venglustat malate Overview

Venglustat malate (GZ-402671) is under development for the treatment of Fabry disease, autosomal dominant polycystic kidney disease, GM1 gangliosidosis, GM2 gangliosidosis (Tay-Sachs disease and Sandhoff disease), saposin C deficiency, sialidosis type 1 or juvenile adult galactosialidosis and Gaucher disease type III. The drug candidate is administered orally as a capsule. The drug candidate targets glucosylceramide synthase (GCS). It is a new molecular entity (NME). It was under development for Parkinson's disease with GBA mutation.

Sanofi Overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.

Quick View – Venglustat malate

Report Segments
  • Innovator
Drug Name
  • Venglustat malate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.